Theralase Technologies Inc. (TLT) - Total Assets
Based on the latest financial reports, Theralase Technologies Inc. (TLT) holds total assets worth CA$3.00 Million CAD (≈ $2.17 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See TLT total equity for net asset value and shareholders' equity analysis.
Theralase Technologies Inc. - Total Assets Trend (2001–2024)
This chart illustrates how Theralase Technologies Inc.'s total assets have evolved over time, based on quarterly financial data.
Theralase Technologies Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Theralase Technologies Inc.'s total assets of CA$3.00 Million consist of 48.8% current assets and 51.2% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 8.3% |
| Accounts Receivable | CA$166.66K | 5.1% |
| Inventory | CA$545.05K | 16.8% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2001–2024)
This chart illustrates how Theralase Technologies Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see TLT stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Theralase Technologies Inc.'s current assets represent 48.8% of total assets in 2024, a decrease from 99.3% in 2001.
- Cash Position: Cash and equivalents constituted 8.3% of total assets in 2024, down from 99.3% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2001.
- Asset Diversification: The largest asset category is inventory at 16.8% of total assets.
Theralase Technologies Inc. Competitors by Total Assets
Key competitors of Theralase Technologies Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
INKON Life Technology Co Ltd
SHE:300143
|
China | CN¥4.15 Billion |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
China | CN¥988.48 Million |
|
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS
|
USA | $139.92 Million |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO
|
India | Rs8.57 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
|
Aligned Genetics Inc
KQ:238120
|
Korea | ₩45.11 Billion |
|
Heramed Ltd
AU:HMD
|
Australia | AU$1.04 Million |
|
Acarix A/S
ST:ACARIX
|
Sweden | Skr48.33 Million |
Theralase Technologies Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.83 | 1.91 | 10.85 |
| Quick Ratio | 0.57 | 1.21 | 10.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-299.03K | CA$788.44K | CA$8.09 Million |
Theralase Technologies Inc. - Advanced Valuation Insights
This section examines the relationship between Theralase Technologies Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 75.15 |
| Latest Market Cap to Assets Ratio | 18.00 |
| Asset Growth Rate (YoY) | -0.9% |
| Total Assets | CA$3.25 Million |
| Market Capitalization | $58.45 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Theralase Technologies Inc.'s assets at a significant premium (18.00x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Theralase Technologies Inc.'s assets decreased by 0.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Theralase Technologies Inc. (2001–2024)
The table below shows the annual total assets of Theralase Technologies Inc. from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CA$3.25 Million ≈ $2.35 Million |
-0.91% |
| 2023-12-31 | CA$3.28 Million ≈ $2.37 Million |
-21.25% |
| 2022-12-31 | CA$4.16 Million ≈ $3.01 Million |
-30.01% |
| 2021-12-31 | CA$5.94 Million ≈ $4.30 Million |
-40.67% |
| 2020-12-31 | CA$10.02 Million ≈ $7.25 Million |
-35.22% |
| 2019-12-31 | CA$15.47 Million ≈ $11.19 Million |
+334.01% |
| 2018-12-31 | CA$3.56 Million ≈ $2.58 Million |
+7.27% |
| 2017-12-31 | CA$3.32 Million ≈ $2.40 Million |
-46.76% |
| 2016-12-31 | CA$6.24 Million ≈ $4.51 Million |
-12.13% |
| 2015-12-31 | CA$7.10 Million ≈ $5.14 Million |
+86.06% |
| 2014-12-31 | CA$3.82 Million ≈ $2.76 Million |
+42.17% |
| 2013-12-31 | CA$2.68 Million ≈ $1.94 Million |
+137.04% |
| 2012-12-31 | CA$1.13 Million ≈ $819.34K |
-19.72% |
| 2011-12-31 | CA$1.41 Million ≈ $1.02 Million |
-56.41% |
| 2010-12-31 | CA$3.24 Million ≈ $2.34 Million |
-22.77% |
| 2009-12-31 | CA$4.19 Million ≈ $3.03 Million |
+31.72% |
| 2008-12-31 | CA$3.18 Million ≈ $2.30 Million |
-14.18% |
| 2007-12-31 | CA$3.71 Million ≈ $2.68 Million |
+0.61% |
| 2006-12-31 | CA$3.68 Million ≈ $2.67 Million |
+3.81% |
| 2005-12-31 | CA$3.55 Million ≈ $2.57 Million |
+192.12% |
| 2004-12-31 | CA$1.22 Million ≈ $878.97K |
+97.59% |
| 2003-12-31 | CA$614.96K ≈ $444.85K |
+527.06% |
| 2002-12-31 | CA$98.07K ≈ $70.94K |
-33.10% |
| 2001-12-31 | CA$146.59K ≈ $106.04K |
-- |
About Theralase Technologies Inc.
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. It designs, develops, m… Read more